ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Houston, TX

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near Houston, TX, USA:

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast...

Enrolling
Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
Drug: OTS167PO

Phase 1

OncoTherapy Science

Houston, Texas, United States and 3 other locations

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. -...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Pembrolizumab
Drug: ladiratuzumab vedotin

Phase 1, Phase 2

Seagen
Seagen

Houston, Texas, United States and 49 other locations

Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer

dual mechanism kinase inhibitor targeting both mitosis and tumor micro-environment, for the treatment of triple negative b ...

Active, not recruiting
Advanced Solid Tumors
Triple Negative Breast Cancer
Drug: TT-00420

Phase 1

TransThera Sciences

Houston, Texas, United States and 1 other location

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)

oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoin ...

Active, not recruiting
Breast Cancer
Renal Cell Carcinoma
Drug: nab-paclitaxel
Drug: Bevacizumab

Phase 2

Infinity Pharmaceuticals
Infinity Pharmaceuticals

Houston, Texas, United States and 23 other locations

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC).The Following drugs will be ...

Active, not recruiting
Inflammatory Breast Cancer (IBC)
Drug: Paclitaxel
Drug: Cyclophosphamide

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Houston, Texas, United States and 3 other locations

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple ne ...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Atezolizumab
Drug: Placebo

Phase 3

National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP)

Houston, Texas, United States and 216 other locations

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe)

avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage I...

Enrolling
Stage IIIA Breast Cancer
Recurrent Breast Carcinoma
Biological: Utomilumab
Biological: Anti-OX40 Antibody PF-04518600

Phase 2

Hope Rugo, MD

Houston, Texas, United States and 11 other locations

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Houston, Texas, United States and 165 other locations

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

To learn if sacituzumab govitecan and pembrolizumab, when given before surgery, can help to control early-stage triple negative breast...

Enrolling
Breast Cancer
Drug: Sacituzumab Govitecan
Drug: Pembrolizumab

Phase 2

M.D. Anderson Cancer Center
M.D. Anderson Cancer Center

Houston, Texas, United States

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST)

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Placebo
Drug: Niraparib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Houston, Texas, United States and 199 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems